AndhraNews.net
Home » Business News » 2012 » March » March 20, 2012

MorphoSys to Present at Kempen & Co. Healthcare/Life Sciences Conference 2012


March 20, 2012 - Martinsried, Germany And Munich, Germany


MorphoSys AG /MorphoSys to Present at Kempen & Co. Healthcare/Life SciencesConference 2012.

Processed and transmitted by Thomson Reuters ONE.

The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced todaythat itsmanagement will present at the upcoming Kempen & Co. Healthcare/LifeSciencesConference 2012 in Amsterdam (The Netherlands).


Kempen & Co. Healthcare/Life Sciences Conference 2012
Date: March 22, 2012
Venue: Amsterdam, The Netherlands
Participants: Dr. Simon Moroney, CEO of MorphoSys AG;
Dr. Claudia Gutjahr-Loser,
Head of Corporate Communications & IR

The PDF version of the presentation will be provided at www.morphosys.com

About MorphoSys:

MorphoSys developed HuCAL, the most successful antibody library technologyinthe pharmaceutical industry. By successfully applying this and otherpatentedtechnologies, MorphoSys has become a leader in the field of therapeuticantibodies, one of the fastest-growing drug classes in human healthcare.TheCompany's AbD Serotec unit uses HuCAL and other technologies to generatesuperior monoclonal antibodies for research and diagnostic applications.Through its own development efforts and successful partnerships in thepharmaceutical industry, MorphoSys has built a therapeutic pipeline of morethan70 human antibody drug candidates for the treatment of cancer, rheumatoidarthritis, and Alzheimer's disease, to name just a few. With its ongoingcommitment to new antibody technology and drug development, MorphoSys isfocusedon engineering the medicines of tomorrow. MorphoSys is listed on theFrankfurtStock Exchange under the symbol MOR. For regular updates about MorphoSys,visithttp://www.morphosys.com


HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®andarYla® are registered trademarks of MorphoSys AG. Ylanthia® and 100billionhigh potentials™ are trademarks of MorphoSys AG.

Slonomics® is a registered trademark of Sloning BioTechnologyGmbH, asubsidiary of MorphoSys AG.

This communication contains certain forward-looking statementsconcerning theMorphoSys group of companies. The forward-looking statements containedhereinrepresent the judgment of MorphoSys as of the date of this release andinvolverisks and uncertainties. Should actual conditions differ from theCompany'sassumptions, actual results and actions may differ from thoseanticipated.MorphoSys does not intend to update any of these forward-lookingstatements asfar as the wording of the relevant press release is concerned.

Conference Announcement (PDF):http://hugin.info/130295/R/1595821/502594.pdf

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE[HUG#1595821]


For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Loser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

Email Contact

MarketWire

Comment on this story

Share